Patent ID: 8894968

Claim:
A pharmaceutical agent containing a particulate inorganic matrix, which in addition to the natural isotope distribution of the structure type-forming elements of anions or cations, contains contents of positron-emitting nuclides, wherein at least some of the positron-emitting nucleotides form part of the matrix, wherein the structure type forming elements comprise amorphous structures or a mixture of amorphous structures and crystal structures, wherein the number of positron-emitting nuclides per particulate inorganic matrix is greater than or equal to 1, wherein the particulate inorganic matrix is selected from the group consisting of topaz (Al 2 F 2 )[SiO 4 ], chiolite Na[Al 3 F 4 ], wavellite Al 3 (PO 4 ) 2 (OH,F) 2 , calcium carbonate (CaCO 3 ), maghemite (γ-Fe 2 O 3 ), zeolites, magnetite (Fe 3 O 4 ), barium sulphate (BaSO 4 ), gallium phosphate (GaPO 4 ), apatite or fluorohydroxyapatite (Ca 5 (PO 4 ) 3 (OH,F)=3Ca 3 (PO 4 ) 2 *Ca(OH,F) 2 ) and fluorspar (CaF 2 ), wherein the particulate inorganic matrix is coupled to a target-specific ligand and wherein the positron-emitting nuclides are selected from the group consisting of [15]O, [30]P, [13]N, [65]Ga, [11]C, [131]Ba, [26]Al, [68]Ga and [18]F.